Physician profile
James M Campbell
NPI 1144290982
$3,318.39
in general payments reported to CMS, 2019-2025
29 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $395 · 2021: $566 · 2022: $295 · 2023: $413 · 2024: $493 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $414.54 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $393.37 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $383.46 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $363.77 | 2020-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $302.51 | 2021-2025 | Verquvo, Lagevrio |
| Novartis Pharmaceuticals Corporation | $242.65 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $227.25 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $187.35 | 2019-2024 | |
| Novo Nordisk INC | $123.33 | 2022-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.10 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $63.89 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $60.76 | 2019-2021 | |
| Astellas Pharma US INC | $57.59 | 2019-2021 | |
| Medtronic Vascular, INC. | $52.03 | 2020 | |
| Esperion Therapeutics, INC. | $41.62 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $33.80 | 2025 | Inspire |
| Scpharmaceuticals INC. | $33.74 | 2023-2024 | |
| Abbott Laboratories | $31.75 | 2025 | Optis |
| Philips North America LLC | $28.38 | 2023-2024 | (Cm9) Amb Mon & Diag Und |
| Amarin Pharma, INC. | $24.37 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $23.57 | 2023 | Inpefa |
| Edwards Lifesciences Corporation | $23.36 | 2019 | |
| Csl Behring | $18.23 | 2021 | |
| Boston Scientific Corporation | $18.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.47 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.84 | 2025 | Amvuttra |
| Daiichi Sankyo INC. | $14.76 | 2020 | |
| Akcea Therapeutics, INC. | $14.05 | 2019 | |
| Chiesi USA, INC. | $12.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.